Kornimate/medical-research-clean huggingface dataset:
stage i multiple myeloma treatment

Conditions: Multiple Myeloma

Summary: * assessment of survival without progression of stage i mm in two groups: arm a: simple survey and arm b: administration of zoledronate. * describe different progression's type noticed and define the prognosis factors of a fast evolution.

rational: multiple myeloma in spite of therapy progresses mainly due to stem cell auto transplant, still remain a deadly disease. about 2000 new cases are diagnosed every year in france. the asymptomatic stage i mm according to duries and salmon's staging are usually only watch over and only treated at progression. zoledronate is a third generation aminobiphosphonate (bp), probably the most powerful among the available compounds which received market clearance authorisation in mm with bone damage. during mm, bone's hyper resorption is premature. interactions exist between tumor growth and bone lyses. zoledronate's got a proper antimyeloma's action (induce plasma cells apoptosis). we propose to test the early use of zoledronate as soon as stage i mm to delay progression. study's objectives: * principal: assessment of survival without progression stage i mm in two groups: a arm: simple survey and b arm: administration of bp. * secondary: describe different progression's type noticed (bone/extra bone) and define the prognosis factor of a fast stage i mm evolution (standard factors, cytogenetic 13 deletion, bone's restructuring strains: crosslaps, bone alkaline phosphatase), list side effects. study's kind: multicenter international randomised trial, open labelled, with individual profit. contributing centers: intergroupe francophone du myélome's centers. inclusions criteria: asymptomatic stage i mm without bone's lesion on the standard radiographs. study's monitoring: after checking inclusion and non inclusion specifications, the patient will be included in the study and randomized (a arm or b arm) before all treatment. the randomisation will be done by center and stratified according to the diagnostic date witch a year or not. * arm a: simple survey as standard practice. * arm b: a 15 minutes infusion of zoledronate every month until progression or a maximum of 18 infusions if no progression. the exams are the one usually defined according to good clinical practices guidelines besides cytogenetic, bone's restructuring strain and serum creatin dosage before each infusion in b arm. statistical purposes: the minimum number of patients required showing a median survival time increase without progression of 26 months in the control arm and 38 months in the bp arm is about 175 patients in each arm for a 48 months inclusion's period, and a monitoring of 24 months after the last inclusion (i.e. a study's length of 6 years).

Eligibility criteria:
inclusion criteria: * stage i multiple myeloma without bones injuries exclusion criteria: * abnormal kidney function * vih infection * hepatic incapacity * pregnancy * associate pathology

Keywords: stage i multiple myeloma
beta cell imaging during and shortly after the honeymoon phase of t1d

Conditions: Type 1 Diabetes Mellitus

Summary: the primary goal is to correlate beta cell mass to beta cell function from measurements during and shortly after the honeymoon phase of type 1 diabetes, to improve understanding of the change in metabolic control after the honeymoon phase.

the exact role of beta cell mass during the development and course of diabetes is still poorly understood. further research on beta cell mass is essential to obtain more insights that might aid in the development of diabetes treatment. this study aims at a specific phase of t1d that is called the 'honeymoon phase' or period of partial remission. once insulin treatment has started, the honeymoon phase will arise in most patients. in this period, t1d patients become temporarily less insulin-dependent. unfortunately, the honeymoon phase is only temporary, in which a decline in blood glucose regulation will be seen afterwards, leading to an increasing demand for insulin. to increase understanding of this change in metabolic control after the honeymoon phase, repeated measurements of the beta cell mass and function are performed during and shortly after the honeymoon phase. the comparison of both measurements might lead to an increased understanding whether changes in insulin demand after the honeymoon phase is mainly dependent on a decline in the beta cell mass, or because of a decrease in functional beta cells. the outcome of this study can provide new insights, which can contribute to the development of novel treatment options.

Eligibility criteria:
inclusion criteria: * age ≥ 16 years * diagnosed with t1d * presence of anti-gad * subject is in honeymoon phase * 17 ≤ bmi ≥ 30 kg/m\^2 at moment of visit * ability to sign informed consent exclusion criteria: * previous treatment (within 6 months) with synthetic exendin (exenatide, byetta®) or dipeptidyl-peptidase iv inhibitors * liver disease * renal disease * pregnancy or the wish to become pregnant within 6 months after the study * breastfeeding * bmi \ 30 kg/m2 * age \<16 years * when the end of the honeymoon phase is not observed within 11 to 13 months after the inclusion of the subject * inability to sign informed consent
kegel exercises for stress urinary incontinence

Conditions: Urinary Incontinence,Stress

Summary: study about a targeted group of women suffering from self-reported stress urinary incontinence, attend a kegel exercise training program. the group was divided into two; supervised and unsupervised. whilst both groups benefited from initially seeing a women's health physiotherapist for a pelvic floor muscle assessment and a bespoke kegel exercise program, only the supervised group continued to see the physiotherapist for monthly bio-feedback training. the unsupervised group relied on their own motivation to perform their kegel exercises as prescribed. at the end of the twelve week program, both groups had a final pelvic floor muscle strength assessment by the physiotherapist to determine any changes and subsequent improvements in urinary incontinence. aim : investigate and compare the efficacy of supervised kegel exercises with biofeedback on stress urinary incontinence (sui) and pelvic floor muscle strength (pfms) compared to unsupervised kegel exercises. the primary goal of this study was to determine the effectiveness of supervised kegel exercises using bt versus unsupervised kegel exercises without biofeedback training, on sui. a secondary outcome was to establish whether an improvement was observed in pfms and subsequently, the effect of this on sui. it was hypothesized that regular support and visual motivation and direction of bt from the physiotherapist, would provide greater results.


Eligibility criteria:
inclusion criteria: * being female * aged over 18 years * suffer from sui (their subjective disclosure was based on a description provided for their reference) * did not perform kegel exercises * be available for duration of 12-week program exclusion criteria: * pregnancy and breastfeeding
effect of vit d on new-onset af in hypertension

Conditions: Atrial Fibrillation; Hypertension

Summary: atrial fibrillation (af), an important cause of cardiac mortality and morbidity is the most common type of cardiac arrhythmia in clinical practice. hypertensive individuals are at particular risk of development of atrial fibrillation. renin-angiotensin-aldosteron system (ras) which is activated in hypertension may be the underlying mechanism of af among hypertensive patients. vitamin d deficiency has been shown to be involved in the pathogenesis of hypertension, cardiovascular disease and obesity. increased ras activity is one of the postulated mechanisms by which vitamin d deficiency may trigger the development of hypertension and various cardiovascular diseases. on the basis of these data we hypothesized that hypovitaminosis d might be associated with new-onset af among patients with hypertension.


Eligibility criteria:
inclusion criteria: * hypertensive patients with new-onset af exclusion criteria: established coronary artery disease * heart failure * chronic obstructive pulmonary disease * diabetes mellitus * significant heart valve disease * hyperthyroidism * renal failure * any malignancy * acute infection * recent thoracic or abdominal surgery * under therapy of vit d3

Keywords: atrial fibrillation, hypertension, vitamin d
peri-neural dexmedetomidine as an adjuvant to bupivacaine induced paravertebral block in patients undergonig thoracotomy

Conditions: Acute Post-thoracotomy Pain

Summary: this study evaluates the effect of adding dexmedetomidine as an adjuvant to bupivacaine in patients undergoing thoracotomy when administered peri-neurally in thoracic paravertebral space.

thoracotomy is associated with severe postoperative pain that could be reduced with an aggressive analgesic therapy in the early postoperative period. the use of thoracic paravertebral block is an effective analgesic approach for post-thoracotomy pain. several local anesthetic adjuvants have been reported to extend the duration of paravertebral block. alpha-2 agonists including dexmedetomidine appear to be the most effective in this context. the study will include an intervention group which will receive a combination of 20 ml bupivacaine 0.5% and dexmedetomidine 0.5 ml (50 microgram). the control group will receive 20 ml bupivacaine 0.5% plus 0.5 ml normal saline perineurally. thoracic paravertebral catheter will be inserted preoperatively. visual analogue pain score will be assessed at different intervals.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status class \|\|or \|\|\|. * patients scheduled for elective thoracotomy. exclusion criteria: * pneumonectomy, decortication, pleural biopsy. * additional chest wall resection. * emergency surgery. * central and peripheral neuropathies.
clinical phenotype and outcomes of inpatients with covid-19 and diabetes

Conditions: Diabetes Mellitus; Covid19

Summary: patients with diabetes have been listed as people at higher risk for severe illness from covid-19. moreover, the relationship between diabetes-related phenotypes and the severity of covid-19 remains unknown. this observational study aims to to evaluate the risk of disease severity and mortality in association with diabetes in covid-19 inpatients and identify the clinical and biological features associated with worse outcomes.

the epidemic of coronavirus disease-2019 (covid-19), a disease caused by the severe acute respiratory syndrome-coronavirus-2 (sars-cov-2) virus, rapidly spread worldwide and was declared a pandemic by the world health organization on 11 march 2020. it is well known that people with diabetes have increased infection risk, especially for influenza and pneumonia. moreover, diabetes was previously reported as a major risk factor for mortality in people infected with the h1n1 pandemic influenza and, more recently, with the middle east respiratory syndrome-related coronavirus (mers-cov) . epidemiological studies have quickly and consistently pointed out diabetes as one of the major comorbidities associated with covid-19 and affecting its severity. the prevalence of diabetes in patients with covid-19 was first reported to range from 5% to 20%. furthermore, the covid-19-associated hospitalisation surveillance network (covid-net) reported a diabetes prevalence of 28.3% in hospitalised patients in the usa. more importantly, all studies published so far have reported a two- to threefold higher prevalence of diabetes in patients in icus compared with those with less severe disease and an increased mortality in people with diabetes. a recent meta-analysis further demonstrated that diabetes was associated with a more than doubled risk for icu admission and a more than tripled risk for death. however, precise data regarding diabetes characteristics in hospitalised people with covid-19 are still lacking. moreover, the relationship between diabetes-related phenotypes and the severity of covid-19 remains unknown. this study aims to identify the clinical and biological features and potential interactions of diabetic therapies associated with disease severity and mortality risk in people hospitalised for covid-19. hospital medical records of inpatients, hospitalized between february 23 to march 31 2020, at the internal medicine unit dedicated to covid-19 in the academic hospital of parma, italy will be analysed.

Eligibility criteria:
inclusion criteria: * admission with covid-19 to the internal medicine unit dedicated to covid-19 (macrounit 1), academic hospital in parma (italy) between february 23 to march 31 2020. exclusion criteria: * during hospitalization inter or intra-hospital transfer of inpatients

Keywords: diabetes covid-19 inhospital mortality intensive care unit
validation study on eye rubbing questionnaire in patients with or suspected of having a keratoconus (kc)

Conditions: Keratoconus

Summary: kc is a degenerative disorder of the cornea. keratoconus etiopathogenesis remains unclear and may rely on environmental and genetic factors. usually considered as a rare disease (\<1/2000), but the prevalence is nowadays growing worldwide up to 1/500. in that pathology, cornea progressively gets thinner, and there is a deformation of the corneal surface which can induce high order optical aberrations and visual impairment. eye rubbing is certainly the main factor in the progression or development of keratoconus (kc), yet it is only very partially evaluated and quantified in current management. environmental and clinical factors will be collected and associated with a eye rubbing questionnaire, specifically pointing out eye rubbing.

cnrk center is working on an eye rubbing questionnaire since 2017 in order to quantify that pejorative factor. patient education can limit in a certain amount the keratoconus progression. thus, our objective will be to evaluate the therapeutic impact on keratoconus progression of patient's education against eye rubbing according to an eye rubbing questionnaire. the validation of a dedicated questionnaire is an important act that will allow the scientific evaluation of this factor with both environmental and behavioral traits. it can thus be integrated into our care activity for its intrinsic educational and therapeutic virtues and for its decision-making aid for certain treatments. it will be useful first of all for the refinement of the correct prescription of corneal collagen crosslinking for evolving kc or kc with a high risk of progression.

Eligibility criteria:
inclusion criteria: * coming for the first time for expert advice on kc * having a suspected or known kc * being over 13 years old (or from 13 years old) * possess computer connection equipment (computer, tablet or smartphone) and access to the network, for the completion of the questionnaire at home. * being affiliated to or beneficiary of health insurance * have signed the informed consent form from the patient and from legal representatives for minor patient exclusion criteria: * being incapacitated or unable to follow study procedures * patient under legal protection * previous ocular surgery

Keywords: keratoconus eye rubbing
delineation of the role of glucagon-like peptide-1 signalling in relation to increased carbohydrate content in the distal small intestines

Conditions: Glucose Metabolism Disorders

Summary: investigation of glp-1 signalling in the glucose-lowering effect of increased carbohydrate content in the distal small intestines induced by alpha-glucosidase inhibition during meal ingestion in patients with type 2 diabetes

the primary aim of the study is to investigate whether glp-1 released as a result of increased carbohydrate content in the distal and l cell-rich part of the small intestine after a meal affects postprandial plasma glucose levels in patients with type 2 diabetes. this will be done by applying an alpha-glucosidase inhibitor (to increase the postprandial carbohydrate content in the distal small intestine) and the specific glp-1 receptor antagonist exendin(9-39) (to isolate any glp-1-mediated effects) during meal tests in patients with type 2 diabetes.

Eligibility criteria:
inclusion criteria: * type 2 diabetes for at least three months (diagnosed according to the criteria of the world health organization (who)) treated with metformin monotherapy * caucasian ethnicity * normal haemoglobin * age \>18 years * bmi \>23 kg/m2 and \<35 kg/m2 * informed and written consent exclusion criteria: * liver disease (alanine aminotransferase (alat) and/or serum aspartate aminotransferase (asat) \>2 times normal values) or history of hepatobiliary disorder * gastrointestinal disease, previous intestinal resection, cholecystectomy or any major intra-abdominal surgery * reduced kidney function or nephropathy (estimated glomerular filtration rate (egfr) \<60 ml/min/1.73 m2 (based on serum creatinine) and/or albuminuria * treatment with medicine that cannot be paused for 12 hours * intake of antibiotics two months prior to study * treatment with glucose-lowering drugs other than metformin * hypo- and hyperthyroidism * treatment with oral anticoagulants * active or recent malignant disease * any treatment or condition requiring acute or sub-acute medical or surgical intervention * lack of effective birth control in premenopausal women * positive pregnancy test on study days in premenopausal women * pregnancy * women who are breastfeeding * any condition considered incompatible with participation by the investigators * if the subjects receive any antibiotic treatment while included in the study they will be excluded

Keywords: glp-1 alpha-glucosidase inhibitor acarbose
poor grade aneurysmal subarachnoid hemorrhage study group

Conditions: Subarachnoid Hemorrhage, Aneurysmal; Poor Grade Subarachnoid Hemorrhage

Summary: multicentric registry study in order to define outcome, predictors, treatment effects and their modifiers in poor grade aneurysmal subarachnoid haemorrhage patients. the search for outcome predictors is going to be subdivided into three main research areas: 1. outcome predictors in the emergency department (so called "early brain injury phase"). 2. outcome predictors in the neurocritical care unit (so called "delayed brain injury phase"). 3. treatment strategies. two other areas of research are identified: delayed cerebral ischemia (incidence, treatment, predictors, impact on outcome) and long term follow-up (recent evidences suggest that there may be a non-negligible proportion of poor grade subarachnoid hemorrhage patients who may benefit from substantial improvement at long-term (after 6-12 months of follow-up).


Eligibility criteria:
inclusion criteria: * patients admitted to the emergency department because of aneurysmal subarachnoid hemorrhage of poor grade (iv-v) according to the wfns classification. exclusion criteria: * patients younger than 18 years old. * pregnant or breast-feeding patients. * aneurysmal subarachnoid hemorrhage due to trauma or vascular malformations other than cerebral aneurysms.
neuroinflammation during icu-associated delirium in critically ill patients and its association with structural and functional brain alterations: a nested case-control study

Conditions: Delirium; Critical Illness

Summary: with the present study, the authors aim to improve the knowledge of the pathophysiology of icu-related delirium. in particular, the authors would like to clarify the possible correlation between neuroinflammation, evaluated longitudinally by serum dosage of 20 different neuroinflammation biomarkers, and brain structural and functional alterations (using brain fmri).

pathophysiology of delirium is poorly understood; neuroinflammation and brain network disruption are claimed as possible causes of delirium. the authors want to clarify the role of the alterations of different cellular components of neuroinflammation (neurons, glial cells, and endothelium) in delirium development. moreover, the authors want to understand whether the neuroinflammation process could cause permanent structural and functional brain damage. in a nested cross-sectional longitudinal case-control observational study in icu admitted patients. the objectives of the studies are as follow: 1) neuroinflammation biomarkers evaluation in non-neurological icu patients who develop delirium during icu-stay (case) compared to matched non-delirious icu patients (control), and 2) their correlation with brain structural and functional alterations evaluated with a resting-state fmri protocol and pet.

Eligibility criteria:
inclusion criteria: * age\>18 * all patients admitted that would be expected to stay in icu for at least 3 days exclusion criteria: * acute neurological condition * chronic neurological condition (i.e., seizures, stroke, muscular illness). * hematological malignancy or immunological disease. * blood transfusion in the last 2 weeks * ongoing sedation * any condition which contraindicates mri execution (presence of non-compatible devices or hemodynamic or respiratory instability).

Keywords: neuroinflammation fmri functional mri icu related delirium
clinical safety study on an eyelid warming device to evaluate the eyelid and cornea temperature in healthy volunteers

Conditions: Eyelid Diseases

Summary: the eyelid warming device is designed to relieve the symptoms of dysfunction of the glands in the eyelids. prospective, non comparative, open, monocentre study. the objectives are: * to verify and establish the temperature of the eyelids and cornea for each eye before and after 10 minutes device application * to evaluate the ocular surface, nibut and iop before and after device application * to determine the acceptability of healthy volunteers on the practical use of this device the subjects will attend 2 visits.


Eligibility criteria:
inclusion criteria: * male or female aged from 18 to 80 years old. * healthy volunteers. * for any contact lens wearers, they must be wearing hydrogel contact lenses (worn at least 3 times per week) * normal ocular examination in both eyes.
evaluation of yoga for the treatment of pediatric headaches

Conditions: Headache

Summary: this study will examine the feasibility and acceptability of yoga for adolescents seen by a medical practitioner for their headaches. the study will also examine whether yoga decreases anxiety and improves quality of life. we hypothesize that yoga will be both acceptable and feasible with a pediatric population. we also hypothesize that yoga will decrease anxiety and improve quality of life.


Eligibility criteria:
inclusion criteria: * 13-17 years * patient seen in the headache clinic at children's hospital of wisconsin exclusion criteria: * neck, spinal, or back injuries

Keywords: headache complementary and alternative medicine pediatric yoga